From Nasdaq.: 2025-05-31 00:38:00

A study by Teva Pharmaceuticals revealed that only 1.1% of long-term care residents on antipsychotic drugs had a confirmed diagnosis of tardive dyskinesia. Less than half of those with TD received the recommended standard of care treatment. Many residents were treated with non-FDA approved options or not treated at all. The study highlighted the need for better evaluation and treatment of TD in LTC facilities to ensure proper care for residents. This underscores the challenge of identifying and treating TD in this population. More intensive evaluation is needed to improve diagnosis and treatment.



Read more at Nasdaq.: Teva Study Highlights Gaps In Tardive Dyskinesia Diagnosis And Treatment In LTC Facilities